Miles Prince Q&A Update
Prescient Therapeutics: Q&A Update with Professor H. Miles Prince Reach Markets recently interviewed Professor H....
Prescient Therapeutics: Q&A Update with Professor H. Miles Prince Reach Markets recently interviewed Professor H....
Prescient Therapeutics: Mariam Mansour, PhD Mariam Mansour, PhD, Director of Clinical Development and Translational Sciences...
Prescient Therapeutics: Professor H. Miles Prince Professor H. Miles Prince AM, the Principal Investigator for...
Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke CEO and Managing Director,...
Pitt Street Research Briefing on Prescient Therapeutics (ASX: PTX) Reach Markets interviewed Co-Founder and Senior...
Prescient Therapeutics: PTX-100 targeted cell therapy briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke gave...
Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke CEO and Managing Director,...
Prescient was pleased to present data on our cell therapies at the prestigious International Society...
Prescient Therapeutics: Cell Therapies presentations from ISCT Prescient Therapeutics held a special Cell Therapies briefing...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.